Skip to main content
Premium Trial:

Request an Annual Quote

Martin Madaus, Gregory Gosch, Ludwig Huber, John Hanlon, and James Mihlik

Premium

Millipore said yesterday that it has appointed Martin Madaus as president and CEO, effective no later than Feb. 1, 2005. Maduas will replace Francis Lunger, who will remain as chairman of the board during the transition. Maduas will also join Millipore’s board of directors, the company said.

Maduas joins Millipore from Roche Diagnostics, where, as president and CEO, he led a $1.9 billion business with approximately 4,000 employees, Millipore said. Prior to his appointment as president and CEO in 2000, Maduas was vice president of business development at Roche Diagnostics. He has also held positions at Boehringer Mannheim, which was acquired by Roche in 1998. Maduas holds a PhD in veterinary medicine.


Gregory Gosch has been named vice president of marketing at Luminex, the company said last week.

Gosch most recently served as senior director of sales and marketing for Nanogen. He has also held marketing and product management positions for Chiron and Bio-Rad Laboratories, Luminex said.


Ludwig Huber was named compliance fellow for the life sciences and chemical analysis division of Agilent Technologies. His duties will include helping the company identify and evaluate compliance-related initiatives for pharmaceutical laboratory customers. Huber has been at Agilent and parent Hewlett Packard since 1978.


John Hanlon, CFO and executive vice president of Accelrys, will resign on Dec. 31 “to be closer to his family,” according to an 8-K form that Accelrys recently filed with the US Securities and Exchange Commission. James Mihlik, the company’s current worldwide controller, will be acting principal accounting officer while the company looks for a new CFO.

 

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.